Menu
 

Search abstracts


Pristimerin exacerbates injury in conditionally reprogrammed patient-derived lung cancer cells

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Presentation
  • By: TANG, Yubo (Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, China)
  • Co-author(s): Yubo Tang: Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
    Chao Cheng: Department of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
    Xuenong Zou: Department of Orthopaedic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
    Xiao Chen: Department of Pharmacy, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
  • Abstract:

    Background

    Lung cancer is the most common and lethal malignant disease for which the development of efficacious chemotherapeutic agents remains an urgent need. Pristimerin (PRIS), a natural component known from Celastraceae families, exerts anti-tumor effect in several types of cancer. However, the underlying mechanisms involved remains unclear.

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 13 May 2019

FIP Congresses